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ABSTRACT
To investigate the amount that radiation-induced secondary cancer would be reduced by using proton beam therapy
(PBT) in place of intensity-modulated X-ray therapy (IMXT) in pediatric patients, we analyzed lifetime attributable
risk (LAR) as an in silico surrogate marker of the secondary cancer after these treatments. From 242 pediatric patients
with cancers who were treated with PBT, 26 patients were selected by random sampling after stratiﬁcation into four
categories: (i) brain, head and neck, (ii) thoracic, (iii) abdominal, and (iv) whole craniospinal (WCNS) irradiation.
IMXT was replanned using the same computed tomography and region of interest. Using the dose–volume histo-
grams (DVHs) of PBT and IMXT, the LARs of Schneider et al. were calculated for the same patient. All the
published dose–response models were tested for the organs at risk. Calculation of the LARs of PBT and IMXT based
on the DVHs was feasible for all patients. The means ± standard deviations of the cumulative LAR difference
between PBT and IMXT for the four categories were (i) 1.02 ± 0.52% (n = 7, P = 0.0021), (ii) 23.3 ± 17.2%
(n = 8, P = 0.0065), (iii) 16.6 ± 19.9% (n = 8, P = 0.0497) and (iv) 50.0 ± 21.1% (n = 3, P = 0.0274), respectively
(one tailed t-test). The numbers needed to treat (NNT) were (i) 98.0, (ii) 4.3, (iii) 6.0 and (iv) 2.0 for WCNS,
respectively. In pediatric patients who had undergone PBT, the LAR of PBT was signiﬁcantly lower than the LAR of
IMXT estimated by in silico modeling. Although a validation study is required, it is suggested that the LAR would be
useful as an in silico surrogate marker of secondary cancer induced by different radiotherapy techniques.
KEYWORDS: radiation-induced, secondary cancer, proton beam therapy, intensity-modulated radiotherapy, life-
time attributable risk
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INTRODUCTION
Intensity-modulated X-ray therapy (IMXT) can achieve excellent
dose conformation, even to irregularly shaped target volumes, com-
pared with 3D radiotherapy. Proton beam therapy (PBT) can
achieve conformal irradiation similar to or better than IMXT. Since
PBT can reduce the low dose regions outside the target volume
compared with IMXT, it is generally thought that the risk of
radiation-induced secondary cancer is lower for PBT than for IMXT
[1]. However, it has been estimated that a period of at least 30
years would be needed to observe the difference in the incidence of
radiation-induced secondary cancer between PBT and IMXT [2].
Since such a long follow-up period is not practical for a prospective
clinical study, surrogate markers for the incidence of radiation-
induced secondary cancer are strongly warranted.
To ﬁnd a cost-effective way to select patients who should be trea-
ted by PBT rather than IMXT, a model-based approach using normal
tissue complication probability calculations was recently reported for
adult cancers [3]. It may also be reasonable to estimate the risk of
secondary cancers when selecting pediatric patients for treatment
using PBT rather than IMXT. A surrogate marker for secondary can-
cer based on scientiﬁc models and proper parameters is required for
this purpose. Schneider et al. suggested that dose distribution data
from a 3D radiation treatment planning system (3DTPS) based on
computed tomography (CT) images could be used to estimate the
lifetime attributable risk (LAR) of secondary cancer after radiation
therapy [4]. The LAR is based on a long-term observation study of
the atomic bomb survivors in Hiroshima and Nagasaki [5] and of
patients who have received radiotherapy for Hodgkin’s disease [6]. In
this study, we investigated whether the LAR could be used as an ‘in
silico’ surrogate marker for any pediatric cancers, by examining the
amount of difference in the LAR between the different dose distribu-
tions for PBT and IMXT in the same patient.
Applying the method of Schneider et al., we examined the differ-
ence in LAR between PBT and IMXT, using the 3DTPS data for
pediatric patients with tumors who had received PBT in two
Japanese institutions. There have been several reports for whole cra-
niospinal (WCNS) irradiation using the same method, where the
difference would be largest. To date, there have been studies show-
ing that the LAR obtained with PBT is lower than that obtained
with IMXT using a representative scenario for optic glioma and ver-
tebral body Ewing’s sarcoma [7], or brain/head and neck tumors
[8], or WCNS [1, 9–11]. However, it has not been certain whether
the difference in LAR between PBT and IMXT is generally
observed for pediatric patients in any treatment sites or just occurs
in selected patients. To answer this question, in this study we ran-
domly sampled patients from all pediatric patients who were treated
using PBT in two representative institutions in Japan. In addition,
by applying different dose–response models to individual patients,
we evaluated how much the difference between PBT and IMXT
would change according to the selected model.
MATERIALS AND METHODS
Calculation of LAR
There have been three dose–response models applied for determin-
ing the relationship between dose and the risk of radiation-induced
secondary cancer: the linear model, the bell-shaped model and the
plateau model (see Supplementary data). The various organs have
been reported to be best ﬁtted by one or another of these models
[12–17]. Schneider et al. have proposed a ‘full model’, which inte-
grates all three models into one equation [18]. By changing the
parameters in the full model, we can estimate the effect of the differ-
ent dose–response models on the LAR, which is based on dose–
response models as follows:
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Here, D is the dose, R and α′ are organ-speciﬁc model para-
meters (where R is the repopulation parameter and α′ the cell kill
parameter), DT is the prescribed dose and df is the fraction dose.
For sarcoma induction, the following formula was used:
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Computed tomography (CT) and 3DTPS are used to calculate
D, the dose at a certain point in the organ at risk (OAR). The
dose–volume histogram (DVH) of the OAR derived using the CT
data is patient-speciﬁc and treatment-speciﬁc. Therefore, the DVH
can be used to calculate the total risk of secondary cancer of the
OARs in the patient by the following equation.
As the total risk of secondary cancer in the OAR, the organ
equivalent dose (OED) is calculated using DVH and RED as
follows:
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where VT is the total organ volume and V(Di) the dose–volume
histogram.
Using the age at exposure to radiotherapy and the age attained,
excess absolute risk (EAR) at the age attained can be obtained as
follows (Eq. 4). Parameters in the equation were based on the pre-
viously published cancer risk data from A-bomb survivors [5, 19]
and patients receiving radiation therapy for Hodgkin’s disease [13,
15, 20]:
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where βJP is the initial slope of the A-bomb survivors, e the age at
exposure, a the age attained, γe, γα the age modifying parameters,
and s a gender-speciﬁc factor (0.17 and −0.17 for females and
males).
To calculate the risk of secondary cancer throughout the
patient’s life, LAR can be calculated as follows (Eq. 5):
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Here, (a)/(e) is the probability of surviving from age e to age a,
and L is the latent period for solid cancer induction (5 years for
solid cancer and 2 years for leukemia).
The parameters used in the calculation were derived from the
study of Schneider et al. [4]. However, since there were no data
about the thyroid in this paper, data from another paper by
Schneider using a bell-shaped model were used [15]. In the previous
paper, the β value in the EAR calculation was derived from the data
transformed to be applicable for patients in UK [21]. However, since
all the patients in this study were Japanese, we used the original data
from Japanese atomic bomb survivors in this study. The integral area
of LAR was from the attained age plus 5 to 75 years. In addition, the
(a) and (e) values were taken from the 2011 Japanese life table rather
than from the American data in the Schneider’s paper.
In the case that more than one dose–response curve was avail-
able, we calculated the LAR for each dose–response curve along
with the load average of the LAR as the LAR for this patient.
The parameters used in this study is listed in Table 1 for carcin-
oma and Table 2 for sarcoma.
Sampling of the patients
Subjects consisted of 242 patients who were <20 years old and for
whom 3DTPS data were available; these 242 subjects included 143
patients who had been treated using PBT at Tsukuba University
Hospital between 2009 and 2014 and 99 patients at the Shizuoka
Cancer Center who had been treated between 2004 and 2014
(Fig. 1). All patients were treated with PBT with passive scatter
technology. Random sampling was performed by a biostatistitian
(Y.I.). The patients were stratiﬁed into four categories according to
whether they had cancers of (A) the brain, head and neck, (B) the
chest, (C) the abdomen or (D) the whole central nervous system
(WCNS). There were 157, 27, 42 and 16 patients in each category
respectively. In each category, patients were again stratiﬁed accord-
ing to sex (female or male), age (0–6 years old or 7–20 years old),
and target volume (≤median, ≥median) to reduce the bias. After
these stratiﬁcations, 8 patients were randomly selected from the
patients in each of categories (A), (B) and (C). Since the number
Table 1. Schneider’s ﬁt parameters for the various dose–response models for carcinoma induction
Organ at risk Linear model Full model Bell-shaped model Plateau model βJPb γe γa
βb αa R αa αa
Brain 0.44 0.018 0.93 0.009 0.021 0.51 −0.024 2.38
Female breast 0.044 0.15 0.041 0.115 9.2 −0.037 1.7
Lung 0.042 0.83 0.022 0.056 7.5 0.002 4.23
Colon 7.2 0.001 0.99 0.001 0.001 8.0 −0.056 6.9
Stomach 0.46 0.46 0.111 9.5 −0.002 1.9
Small intestine 0.591 0.09 0.48 8.0 −0.056 6.9
Liver 0.22 0.323 0.29 0.243 0.798 4.3 −0.021 3.6
Bladder 0.219 0.06 0.213 0.633 3.2 −0.024 2.38
Thyroid 0.033 0.13 −0.046 0.6
aIn Gy−1.
bIn (10 000 PY Gy)−1. The parameters β, α and R are listed for each organ and each model. The βJP is the initial slope of the A-bomb survivors for age at exposure of
30 and attained age of 70 years and age-modifying parameters γe and γα for various sites.
Table 2. Schneider’s ﬁt parameters for the various dose–response models for sarcoma induction
Organ at risk Low repopulation Intermediate
repopulation
Full tissue recovery γe γa
αa R βb αa R βb αa R βb
Bone 0.019 0.1 1.7 0.067 0.5 0.2 0.078 1.0 0.1 −0.013 −0.56
Soft tissue 0.04 0.1 3.3 0.06 0.5 0.6 0.093 1.0 0.1 −0.013 −0.56
aIn Gy−1.
bIn (10 000 PY Gy)−1. The parameters β , α and R are listed for each organ and for three different values for R (0.1, 0.5 and 1.0). The γe and γa are the age-modifying
parameters for various sites.
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of patients in category (D) who were treated by WCNS was too
small to be randomly sampled, 1 female of age 11, 1 female of age
6, and 1 male of age 3 were selected to represent category (D). In
total, 27 patients were selected by the biostatistician (Table 3).
An external committee consisting of three pediatric radiation
oncologists who are experts in photon therapy assessed the appro-
priateness of the treatment planning of IMXT for the 27 patients.
They evaluated simple clinical data, contouring of targets and
OARs, dose–volume statistics (such as maximum and mean dose
for each organ), dose–volume histograms, and dose distribution on
CT image slice by slice. Two patients (sampling cases C-4, C-6)
were required to be re-planned for IMXT to make the dose distribu-
tion better according to the assessment by the committee. Another
patient in category A (sampling case A-5) was required to be
deleted from subsequent analysis because the patient had been trea-
ted for a relapsed tumor after photon radiotherapy. Compatibility
between IMXT and PBT was conducted in the 26 patients.
Statistical comparison
Digital data concerning the CT image, regions of interest (ROIs),
3D dose distribution, and DVH of the 26 patients were sent to the
central ofﬁce from each institution using the DICOM-RT format in
principle. One of the authors (M.T.), who is a medical physicist, re-
planned the IMXT for each patient using the dose constraint of
each institution and the reference dose constraints from a previous
paper [9]. It was assumed that 6-MV X-ray irradiation was to be
used in IMXT. All the treatment planning for IMXT was based on
the assessment by an external committee made up of three pediatric
radiation oncologists, who used photon therapy to conﬁrm that the
re-planning of IMXT was not intentionally deteriorated and that its
3D dose distribution reached a standard level of conformity and
uniformity. They conﬁrmed that dose–volume statistics for the clin-
ical target volume were equivalent between PBT and IMXT for all
patients. After the approval of the external committee, the OED for
each OAR, the EAR at the age attained, and the LAR for each
patient were calculated for PBT and IMXT, respectively.
The mean and standard deviation among the patients in each
category were calculated and compared using Student’s t-test. The
number needed to treat (NNT) was taken as the number of
patients who required PBT instead of IMXT in order to prevent
one additional incidence of radiation-induced secondary cancer.
Since it is safe to assume that the LAR is smaller with PBT than
IMXT for WCNS, where the irradiation volume is so different, a
one tailed t-test is a reasonable assumption. For other regions, a two
tailed t-test was used for comparison. P values < 0.05 were consid-
ered statistically signiﬁcant. All statistical analyses were performed
using JMP Pro® Version 12 (SAS Institute Inc., Cary, NC).
RESULTS
Calculation of the LARs of PBT and IMXT based on DVH was
feasible for all patients.
The brain, thyroid, bone and soft tissue were selected as the
OARs for PBT and IMXT for the seven patients with tumors of the
brain, head and neck region. For bone and soft tissue, the para-
meters for sarcoma were used. If parameters for pleural models had
been reported, parameters for each model were used to calculate
242 patients <20 years old treated using proton beam therapy
(Tsukuba University: 143 patients; Shizuoka Cancer Center: 99 patients)
Stratified random sampling in four categories
(A : brain, head and neck, B : chest, C : abdomen, D : whole CNS)
A Total : 8/157
A-1 : 1/14
A-2 : 1/16
A-3 : 1/21
A-4 : 1/14
A-5 : 1/16
A-6 : 1/29
A-7 : 1/27
A-8 : 1/20
B Total : 8/27
B-1 : 1/4
B-2 : 1/1
B-3 : 1/6
B-4 : 1/5
B-5 : 1/3
B-6 : 1/4
B-7 : 1/2
B-8 : 1/2
C Total : 8/42
C-1 : 1/4
C-2 : 1/7
C-3 : 1/9
C-4 : 1/7
C-5 : 1/2
C-6 : 1/5
C-7 : 1/6
C-8 : 1/2
D Total : 3/16
D-1 : 1/1
D-2 : 0
D-3 : 0/3
D-4 : 1/1
D-5 : 1/5
D-6 : 0
D-7 : 0/5
D-8 : 0/1
Category X
X-1 : a1b1c1
X-2 : a1b1c2
X-3 : a1b2c1
X-4 : a1b2c2
X-5 : a2b1c1
X-6 : a2b1c2
X-7 : a2b2c1
X-8 : a2b2c2
factor a : sex (a1 : female, a2 : male)
factor b : age (b1 : 7–20 yo, b2 : 0–6 yo)
factor c : target volume or length (c1 : < median value, c2 : > median value )
Figure 1. Schema of stratiﬁed random sampling from patients who had been treated using proton beam therapy at the
Tsukuba University Hospital or Shizuoka Cancer Center.
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the LAR, and the load average value of LAR derived from both
models was used. The difference in LAR between PBT and IMXT,
or the LAR of IMXT minus that of PBT, was calculated for each
OAR (Table 4). If we assume that the LAR of each organ is inde-
pendent of the LAR of other organs, the cumulative risk of
radiation-induced secondary cancer, or cumulative LAR, is calcu-
lated as the sum of the LAR of all organs in the same patient. We
then assume that the LAR of other organs not in the planning CT
scan was zero. The mean of the cumulative LAR of IMXT was sig-
niﬁcantly higher than that of PBT for the brain, bone and soft
tissue (Table 4). The mean ± standard deviation was
1.02 ± 0.52%, and there was a statistical difference (P = 0.0021).
The NNT was 98.0, suggesting that 1 out of 98 patients will not
experience radiation-induced secondary cancer if we use PBT
instead of IMXT.
The female breast, lung, colon, stomach, small intestine, liver,
thyroid, bone and soft tissue were selected as the OARs for 8
patients with tumors of the thoracic region. The mean LAR of
IMXT was signiﬁcantly higher than that of PBT for the lung, stom-
ach, liver, bone and soft tissue (Table 4). The mean ± standard
Table 3. Patient characteristics (category A: brain, head and neck; B: chest; C: abdomen; D: whole central nervous system),
institutions, prescribed radiation dose, and fraction size
Patient Primary pathology Institution Sex Age (year) Fractional dose (Gy) No. of fractions Prescribed dose (Gy)
A-1 Pontine glioma Tsukuba F 11 1.8 30 54
A-2 Germ cell tumor Tsukuba F 12 1.8 17 30.6
A-3 Ependymoma Tsukuba F 2 1.8 28 50.4
A-4 Ewing sarcoma Tsukuba F 2 1.8 28 50.4
A-6 Germ cell tumor Tsukuba M 16 1.8 28 50.4
A-7 Atypical teratoid/rhabdoid tumor Tsukuba M 2 1.8 32 57.6
A-8 Primitive neuroectodermal tumor Shizuoka M 2 1.8 28 50.4
B-1 Ewing sarcoma Tsukuba F 10 1.8 14 25.2
B-2 Pelvic bone, malignancy Shizuoka F 13 2.5 15 37.5
B-3 Rhabdomyosarcoma Tsukuba F 5 1.8 31 55.8
B-4 Neuroblastoma Shizuoka F 1 1.8 20 36
B-5 Pancreatoblastoma Shizuoka M 11 2.0 20 40
B-6 Ewing sarcoma Tsukuba M 19 2.5 24 60
B-7 Ependymoma Tsukuba M 3 1.8 28 50.4
B-8 Neuroblastoma Shizuoka M 3 1.8 20 36
C-1 Pancreatoblastoma Tsukuba F 11 2.5 24 60
C-2 Neuroblastoma Shizuoka F 8 1.8 20 36
C-3 Rhabdomyosarcoma Tsukuba F 2 1.8 25 45
C-4 Neuroblastoma Tsukuba F 3 1.8 17 30.6
C-5 Acinar cell carcinoma Tsukuba M 12 3.3 22 72.6
C-6 Ependymoma Tsukuba M 10 1.8 31 55.8
C-7 Neuroblastoma Tsukuba M 6 1.8 14 25.2
C-8 Neuroblastoma Tsukuba M 4 1.8 17 30.6
D-1 Medulloblastoma Shizuoka F 11 1.8 13 23.4
D-2 Medulloblastoma Shizuoka F 6 1.8 13 23.4
D-3 Medulloblastoma Shizuoka M 3 1.8 10 18
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Table 4. LAR differences between PBT and IMXT and the number needed to treat (NNT) for each organ at risk (Category A: brain, head and neck; B: chest; C:
abdomen; D: whole central nervous system)
Organ at risk A. Brain, H&N B. Chest C. Abdomen D. Whole CNS
LAR diff. (%) NNT P value LAR diff. (%) NNT P value LAR diff. (%) NNT P value LAR diff. (%) NNT P value
Brain 0.77 ± 0.44 131 0.0036** 0.00 ± 0.01 −2.00 × 104 0.230
Female breast 7.46 ± 13.34 13.4 0.158 0.59 ± 1.19 171 0.207 15.9 ± 14.2 6.3 0.0960
Lung 3.23 ± 1.41 31.0 0.0003** 3.76 ± 2.59 26.6 0.0642
Colon 9.22 ± 14.96 10.8 0.125 12.5 ± 19.7 8.0 0.115 22.19 ± 6.94 4.5 0.0156*
Stomach 2.02 ± 1.95 49.6 0.0220* 1.89 ± 1.58 53.0 0.0118* 3.45 ± 2.44 29.0 0.0671
Small intestine 0.63 ± 0.78 160 0.0589 0.72 ± 0.80 139 0.0384* 2.30 ± 2.79 43.4 0.145
Liver 0.60 ± 0.42 166 0.0046** 0.49 ± 0.25 204 0.0009** 1.10 ± 0.14 90.6 0.0026**
Bladder 0.17 ± 0.32 584 0.171 0.14 ± 0.25 698 0.211
Thyroid 0.01 ± 0.01 1.89 × 104 0.356 −0.03 ± 0.13 −3.59 × 103 0.565 1.09 ± 0.18 91.8 0.0046**
Bone 0.08 ± 0.05 1.21 × 103 0.0043** 0.03 ± 0.04 2.95 × 103 0.0455* 0.08 ± 0.07 1.31 × 103 0.0183* 0.03 ± 0.02 3.23 × 103 0.0608
Soft tissue 0.17 ± 0.16 596 0.0335* 0.10 ± 0.09 1.03 × 103 0.0231* 0.20 ± 0.17 506 0.0121*
Cumulative 1.02 ± 0.52 98.0 0.0021** 23.3 ± 17.2 4.3 0.0065** 16.6 ± 19.9 6.0 0.0497* 50.0 ± 21.1 2.0 0.0274*
A two-tailed t-test was used for Category A, B and C regions, and a one-tailed t-test was used for Category D. *P-value < 0.05 and >0.01, and **P-value <0.01.
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deviation of the difference in cumulative LAR was 23.3 ± 17.2%,
and the difference was statistically signiﬁcant (P = 0.0065). The
NNT was 4.3, suggesting that 1 out of 4.3 patients will not experi-
ence radiation-induced secondary cancer if we use PBT instead of
IMXT.
The female breast, colon, stomach, small intestine, liver, bladder,
bone and soft tissue were selected as the OARs for the 8 patients
with cancers of the abdominal region. The mean LAR of IMXT was
signiﬁcantly higher than that of PBT for the stomach, small intes-
tine, liver, bone and soft tissue. The mean ± standard deviation of
the difference in cumulative LAR was 16.6 ± 19.9%, and there was
a statistical difference (P = 0.0497). The NNT was 6.0.
For the 3 patients who were treated with WCNS, the brain,
female breast, lung, colon, stomach, small intestine, liver, bladder,
thyroid and bone were used as the OARs. The mean LAR of IMXT
in the 3 patients was signiﬁcantly higher than that of PBT for the
colon, liver, and thyroid. The mean ± standard deviation of the
cumulative LAR was 50.0 ± 21.1%, and the difference became statis-
tically signiﬁcant by one tailed t-test (P = 0.0274). The NNT was
2.0.
DISCUSSION
The relationship between exposure dose and radiation-induced sec-
ondary cancer has not been totally understood. However, the esti-
mations derived from data on Japanese atomic bomb survivors are
among the most reliable sources for understanding this relationship.
Preston et al. analyzed the incidence of solid cancers among
~105 427 members of the Life Span Study (LSS) cohort of
Hiroshima and Nagasaki atomic bomb survivors [5]. They found
that 17 448 ﬁrst primary cancers were diagnosed from 1958 through
1998. It was estimated that, at age 70 after an exposure at age 30,
the solid cancer rates increased by ~35% per Gy [90% conﬁdence
interval (CI) 28%; 43%] for men and 58% per Gy (90% CI 43%;
69%) for women. For all solid cancers as a group, the excess relative
risk (ERR per Gy) decreases by 17% per decade of increase in age
at exposure (90% CI 7%; 25%) after allowing for attained-age
effects, while the ERR decreased in proportion to the attained age
to the power 1.65 (90% CI 2.1; 1.2) after allowing for age at expos-
ure. The data were consistent with a linear dose response over the
0–2 Gy range, while there was some ﬂattening of the dose response
at higher doses. On the other hand, Dores et al. have examined sec-
ondary cancer incidence among long-term survivors of Hodgkin’s
disease, who were treated with a local dose of up to 40 Gy with
mantle ﬁelds, by a population-based evaluation over 25 years [6].
Among 32 591 patients, there were 2153 secondary cancers
reported, including 1726 solid tumors. The observed-to-expected
ratio was 2.3 (95% CI 2.2; 2.4) for whole secondary cancers and 2.0
(95% CI 1.9; 2.0) for solid tumors. Schneider et al. have extensively
examined the published data on A-bomb survivors in the low dose
range, as well as the cancer risk data of Hodgkin’s disease survivors
in the high dose range. They also reconstructed the dose distribu-
tion of radiotherapy for Hodgkin’s disease and estimated the most
appropriate parameters to describe the relationship between the
absorbed dose and the risk of secondary cancer in the dose range
used in fractionated radiotherapy. Although there are still many
uncertainties in the assumption of radiation-induced cancer in the
radiotherapy dose range, their approach can be regarded as the
most reasonable prediction model at present.
There is a possibility that the superiority of one technique rela-
tive to the others can not be predicted correctly by means of com-
plex equations. For example, if the dose–response curve is not
linear but bell-shaped, the higher dose around the target volume
may not be associated with the increase in the risk of secondary
cancer. In fact, the data are too sparse to select one dose–response
model in many organs. Therefore, it is very important to use the
LAR value with great caution. We think that (i) the LAR value will
only be useful for comparing differences in the dose distribution in
the same patient, (ii) all the dose–response models should be tested
if there is no agreement in the selection of the dose–response mod-
els, (iii) faint differences in the LAR between different treatment
techniques should not be regarded as solid differences, and (iv) stat-
istical analysis should be carefully carried out with the help of bio-
statistics. In the future, if we can update the dose–response curve of
the risk of secondary cancer, it may be possible to improve the use
of the LAR derived from different dose–response models.
As long as we restrict ourselves to the policy above, the present
study suggested that the LAR is useful for quantifying the difference
in the risk of radiation-induced secondary cancer between two treat-
ment techniques in the same patient. For 26 randomly selected
pediatric patients who were treated with PBT, the risk of secondary
cancer was suggested to be statistically lower than it would have
been by treatment with IMXT. As far as we are aware, the number
of patients in our study is the largest to date among studies that
have estimated the risk of radiation-induced secondary cancer. The
number of patients in the previous studies was 2, 2, 6, 10, 6 and 10
patients in Mirabell et al., Paganetti et al., Moteabbed et al., Brodin
et al., Stokkevag et al. and Yoon et al. [1, 7–11], respectively. In this
study, the difference was apparent for the thoracic and abdominal
regions, but not for the brain and head and neck regions in general.
These ﬁndings are consistent with the difference in the ratio of tar-
get volume to total irradiated volume to the patient between PBT
and IMXT. Since the ratio of target volume to irradiated volume is
large in patients who have received PBT for the brain and head and
neck regions, the volume outside of the target volume was so small
that no apparent difference was seen in the risk of secondary can-
cers. This relationship may not have been observed if PBT was used
for the much smaller target volumes for the brain and head and
neck regions. For the thoracic and abdominal regions, the volume
outside the target volume was large enough to see the difference
between PBT and IMXT. Again, this relationship may not have
been observed if PBT was used for much larger target volume for
the thoracic and abdominal regions. For WCNS irradiation, the dif-
ference was quite large.
One shortcoming of this study was that we did not include the
effect of contaminated neutrons in PBT and in high-energy X-ray
therapy. Both treatments are known to increase the contaminated
neutrons compared with conventional conformal radiotherapy [22,
23]. The effect of neutron contamination should be investigated fur-
ther because of the higher risk of secondary cancer of the neutrons.
Newhauser et al. have reported that the effect of neutrons was small
in spot-scanning PBT, although the effect was not negligible in
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passive-scattering PBT [24]. Considering that spot-scanning PBT is
becoming more common than passive-scattering PBT, neutrons are
expected to have an increasingly diminished effect in PBT in clinical
practice. It is also true that as volumetric multiple arc therapy
(VMAT) becomes more popular in IMXT, the treatment time of
IMXT and thus the contamination of neutrons will also be lowered
in IMXT as well.
Another limitation of this study is that we did not completely
validate the model used for the LAR calculation. We should fol-
low up the patients very carefully for years after PBT and IMXT
to conﬁrm whether the differences predicted in this study are
realized.
From the viewpoint of ALARA, the difference in the predicted
risk of secondary cancer between the two treatments was so large
that it is difﬁcult to conduct a comparative study between PBT
and IMXT for some areas. The difference was apparent for the
patients who received WCNS, thoracic and abdominal irradiation.
As long as the goal is to reduce the risk of secondary cancer after
treatment for pediatric cancer, the present study suggested that
PBT has been selected properly for these areas. For the treatment
of the brain and head and neck regions, the difference in the risk
of secondary cancer may not be as large as for the other regions.
Difference in other late adverse reaction rates, such as vascular
damage for pediatric patients between PBT and IMXT, should be
investigated carefully. The total beneﬁt of PBT should be deter-
mined by the total balance between the beneﬁt and risk of various
adverse reactions.
In conclusion, the LAR of radiation-induced secondary cancer
was signiﬁcantly lower when using PBT than when using IMXT
for pediatric patients. The difference was apparent for the thor-
acic region, abdominal region and WCNS irradiation. The results
suggested that it would be reasonable to use the cumulative LAR
difference when we need to select between PBT and IMXT, not
only for pediatric patients but also for other young adult patients.
Even when other in silico surrogate markers, such as normal tis-
sue complication probability and tumor control probability, do
not differ between the two techniques, PBT would be the right
choice for the treatment of pediatric patients in terms of LAR.
However, more work is required for the precise estimation and
long-term validation and updating of the models behind LAR
estimation.
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APPENDIX A. RISK EQUIVALENT DOSE (RED)
A.1 DOSE–RESPONSE MODELS FOR
CARCINOMA INDUCTION
Dose–response models for carcinoma induction by radiation are
expressed by three models: A.1.1, A.1.2 and A.1.3 in principle. A.1.4
is the model proposed by Schneider et al. The risk equivalent dose
(RED) is deﬁned as the dose that produces the equivalent risk of
inducing cancer. RED is the dose that changes with OARs and the
daily dose in fractionated irradiation.
A.1 .1 LINEAR MODEL
( ) = ( )RED D D A1
A.1 .2 BELL-SHAPED MODEL (R→0)
( ) = ( )α− ′RED D D e D A2
A.1 .3 PLATEAU MODEL (R→1)
α
( ) =
′
( )
α− ′
RED D e D A3
A.1 .4 FULL MODEL
( )′α( ) = ′ − − + − ( − )
( )
α
α α
− − −′
′
RED D e D
R
R R e R e D1 2 1 1
A4
D RR2 2 1
α′ = α + β
d
D
Df
T
D: dose; R, α′: organ-speciﬁc model parameters
(R: repopulation parameter; α′ : cell kill parameter);
DT: prescribed dose; df: fraction dose.
A.2 DOSE–RESPONSE MODELS FOR SARCOMA
INDUCTION
For sarcoma induction, the following formula was used:
( )α α( ) = − − + − ( − ) −
( )
′
′ ′
α
α α
−
′
− − ′RED D e D
R
R R e R e RD1 2 1 1 .
A5
D R
R
2 2
1
A dose–response model in case of full repopulation/repair is
derived by taking Eq. A4 to the limit of R = 1:
α
α( ) =
′ (
− − ′ + ) ( )
α
α
− ′
′RED D e D
R
D e1 . A6D
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